Crizotinib (PF-02341066)

Pfizer辉瑞授权 目录号:S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) 克唑替尼是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。

规格 价格 库存 购买数量  
RMB 1812.55 现货
RMB 900.49 现货
RMB 1372.81 现货
RMB 4681.47 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献75篇:

客户使用该产品的13个实验数据:

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Three MET amplified (Hs746t, SNU-5 and MKN45) and two non-amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin antibodies.

    Oncotarget, 2017, 8(31):51675-51687. Crizotinib (PF-02341066) purchased from Selleck.

    Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述 Crizotinib (PF-02341066) 克唑替尼是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。
靶点
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞,作用于c-Met磷酸化作用时具有相似效果,IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞,具有相似的活性,且活力增高,IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时,IC50为13 nM。[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时,与作用于野生型受体相比,效果发生显著改变,IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞,也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比,PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍,作用于IRK和Lck选择性高250多倍,作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反,PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值,为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型,和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长,IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡,IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵,IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射,IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活,和Matrigel入侵,IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞,也有效抑制 NPM-ALK磷酸化,IC50 为24 nM。PF-2341066 有效抑制细胞增殖,伴随着使细胞周期停在G(1)-S期,且诱导 ALK阳性的 ALCL 细胞凋亡,IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 [2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长 (例如,增殖和存活)和转移 (例如,入侵和形成克隆)。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 Mm\qR5l1d3SxeHnjJGF{e2G7 MVG0PEBp MV\EUXNQ MmD2R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCwMlYzKM7:TR?= M1TaVVIyPTd{NUi5
BAF3 MX\DfZRwfG:6aXOgRZN{[Xl? NWHtTnVxPDhiaB?= NHzsNFlFVVOR MonJR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDMNVE6Pk1ibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCyMlIh|ryP NH2z[YszOTV5MkW4PS=>
BAF3 MkHRR5l1d3SxeHnjJGF{e2G7 NFzvSno1QCCq MnrSSG1UVw>? M4DXVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyC5aYToJGlEPTBib3[gNE4zQCEQvF2= MmrHNlE2PzJ3OEm=
Kelly NWK5[|VGS3m2b4TvfIlkKEG|c3H5 MVfEUXNQ NEnocItEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBM\WyueTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjR{IN88US=> MX:yNVU4OjV6OR?=
SH-SY5Y MXHDfZRwfG:6aXOgRZN{[Xl? M3nxcWROW09? MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPTNizszN NInjcGEzOTV5MkW4PS=>
SMS-KCN MUfDfZRwfG:6aXOgRZN{[Xl? MlfBSG1UVw>? M1;zNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNOWy2NQ16gZ4VtdHNiZYjwdoV{e2mwZzDBUGshWjF{N{XRJI12fGGwdDD3bZRpKEmFNUCgc4YhOC57MTFOwG0> NGjMUYEzOTV5MkW4PS=>
BAF3 Mn3lR5l1d3SxeHnjJGF{e2G7 NHvVXlk1QCCq NInBUZlFVVOR NGS5d3FEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiVHXsMWFNUyC5aYToJGlEPTBib3[gNE4yQSEQvF2= MUiyNVU4OjV6OR?=
3T3 MortSpVv[3Srb36gRZN{[Xl? NFyx[5QyKGh? MmXESG1UVw>? MYHJcohq[mm2aX;uJI9nKFKRTjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yODFOwG0> MUCyNVgyOjRzNB?=
3T3-E NUPNR2hHTnWwY4Tpc44hSXO|YYm= NV3pbWRNOSCq MlXBSG1UVw>? NHLjW5lKdmirYnn0bY9vKG:oIGTJSVIh[XO|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>? MYCyNVgyOjRzNB?=
A549 NGTtR|ZMcW6jc3WgRZN{[Xl? Mk\UNUBp NGmzdGxFVVOR NHnpXIFKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IHOtUWVVKGurbnHz[UBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJT0ZvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByODFOwG0> MVGyNVgyOjRzNB?=
BAF3-BCL M2TSWWZ2dmO2aX;uJGF{e2G7 NEXIXVQyKGh? Mnn2SG1UVw>? MYTJcohq[mm2aX;uJI9nKEGETDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOS5zNUmg{txO NHvJ[40zOThzMkSxOC=>
HEK293 NXPCWZBnTnWwY4Tpc44hSXO|YYm= M33YTVEhcA>? M4O0SmROW09? NHH6VnBKdmirYnn0bY9vKG:oIFHYUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6yPVQh|ryP Ml2zNlE5OTJ2MUS=
HEK293 MVvGeY5kfGmxbjDBd5NigQ>? M33afFEhcA>? M4m0fWROW09? NX6xT243UW6qaXLpeIlwdiCxZjDJVkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj64PFch|ryP NVjUS|lyOjF6MUK0NVQ>
Jurkat M4rEV2Z2dmO2aX;uJGF{e2G7 MW[xJIg> MWTEUXNQ Mm\5TY5pcWKrdHnvckBw\iCOQ1ugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwN{SxJO69VQ>? NUPxXJUzOjF6MUK0NVQ>
KARPAS299 MkfPT4lv[XOnIFHzd4F6 M{LGe|EhcA>? NG\lV2ZFVVOR MVzJcohq[mm2aX;uJI9nKEGOSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> MVeyNVgyOjRzNB?=
PAE MVHGeY5kfGmxbjDBd5NigQ>? NFPNdHgyKGh? MVXEUXNQ MXfJcohq[mm2aX;uJI9nKFSUS1KgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwM{m5JO69VQ>? NY\hb3VYOjF6MUK0NVQ>
BAF3 M2PySWZ2dmO2aX;uJGF{e2G7 MX:yMVMh\A>? NFW4eZJFVVOR NUThU|U6UW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgbY5{fWyrbjDy[YNmeHSxcjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDFwNkSzJO69VQ>? NUjuXmVVOjN5NEKyOVI>
KARPAS299 MYXDfZRwfG:6aXOgRZN{[Xl? M1fNZlIuOyCm NH\EU4VFVVOR NFTP[HJKSzVyPUCuNFY1OiEQvF2= MmCyNlM4PDJ{NUK=
EBC1 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne5O|IhcA>? NVfLXYZRTE2VTx?= MYnJR|UxRTBwMEKzJO69VQ>? NVHHU|JvOjN7OUOzNlg>
HCT116 M2\FeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUC3NkBp M3\nfmROW09? M{TVdmlEPTB;MUSuPFIh|ryP NHnqepkzOzl7M{OyPC=>
MCF7 NHPITpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXpcXQ4OiCq NWfnNJgxTE2VTx?= MWPJR|UxRTlwNUig{txO NX[yUWRVOjN7OUOzNlg>
MDA-MB-231 M1fDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H3TlczKGh? NELkXWFFVVOR NYP4Z3BCUUN3ME2xNE45KM7:TR?= MmD5NlM6QTN|Mki=
MKN45 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P5clczKGh? MojiSG1UVw>? MnfzTWM2OD1yLkCxN{DPxE1? MWSyN|k6OzN{OB?=
NCI-H441 M2DLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rvN|czKGh? NFGyO49FVVOR NH3Cd49KSzVyPUG3MlI2KM7:TR?= NHvvUFAzOzl7M{OyPC=>
NCI-H661 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDEOm5UPzJiaB?= MmTXSG1UVw>? MYTJR|UxRTFzLkS3JO69VQ>? MXWyN|k6OzN{OB?=
SK-MEL-28 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLvO|IhcA>? NWPxbXZ{TE2VTx?= NWfm[WlpUUN3ME2xNE46PyEQvF2= MkDTNlM6QTN|Mki=
SKOV3 NFvUTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIiwcJI4OiCq NW\mVJV3TE2VTx?= NX\zd4tXUUN3ME2xNk45PSEQvF2= MkjmNlM6QTN|Mki=
SNU5 NGjWNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj6O|IhcA>? MVjEUXNQ MYDJR|UxRTBwMEG2JO69VQ>? MVuyN|k6OzN{OB?=
NCI-H2228 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXwO|IhcA>? NWDRSmFpTE2VTx?= M2KxTWlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFzODFOwG0> MUOyOFQ{OjlyOR?=
NCI-H3122 NU[5ToJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzzdpM4OiCq MYLEUXNQ MkO1TY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTB6IN88US=> MVyyOFQ{OjlyOR?=
NCI-H3122 NIjsSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvHVJM4OiCq M2Dic2ROW09? M4rG[2lvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIHnuJIh2dWGwIF7DTU1JOzF{MjDj[YxteyCqYYLic5JqdmdiQVzLJGcyOjZ7QTDteZRidnRid3n0bEBKSzVyIH;mJFAvPjJ|IN88US=> NI[yTmQzPDR|MkmwPS=>
NCI-H3122 NXmxPWs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\0flczKGh? NHXXWndFVVOR MnX0TY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugUFEyQT[PIH31eIFvfCC5aYToJGlEPTBib3[gNE45OzhizszN M3nsNVI1PDN{OUC5
NIH-3T3 MVvLbY5ie2ViQYPzZZk> M3m3VlEhcA>? M1fJTmROW09? NFHaRYJKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCHTVy0MYZ2e2WmIFHMT{BmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0[YQhSUyNIHzleoVtKHerdHigTWM2OCCxZjCwMlA5KM7:TR?= NVXBcG1HOjR2M{K5NFk>
NIH-3T3 M4K2W2tqdmG|ZTDBd5NigQ>? Mlv5NUBp MVvEUXNQ M1n0WGlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS|EzPjmDIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNkC1JO69VQ>? MmLQNlQ1OzJ7MEm=
NIH-3T3 NWC5XGZMU2mwYYPlJGF{e2G7 MoPLNUBp M{PHV2ROW09? MknHTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDTNVIxPllibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC54Mk[g{txO NHvEc2gzPDR|MkmwPS=>
NIH-3T3 M4LTRWtqdmG|ZTDBd5NigQ>? NV7NSJA1OSCq M1jYU2ROW09? M3G4e2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyQT[PIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwOESzJO69VQ>? M2q1dlI1PDN{OUC5
NIH-3T3 Mmn1T4lv[XOnIFHzd4F6 NUfiNG9WOSCq NFjWd4RFVVOR NVzY[3g1UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF3MmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6wNlYh|ryP MoDMNlQ1OzJ7MEm=
BAF3 MmXySpVv[3Srb36gRZN{[Xl? M2fY[VczKGh? Mlj2SG1UVw>? NWPBZ4l1UW6qaXLpeIlwdiCxZjDOVG0wSUyNIITyZY5{\mWldHXkJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEWxJO69VQ>? MYSyOFQ3QDZ|Mh?=
BAF3 NW\IdZI{S3m2b4TvfIlkKEG|c3H5 NInmcpU4OiCq M4fkd2ROW09? M2f6d2lEPTB;MD65PEDPxE1? MUmyOFQ3QDZ|Mh?=
NIH-3T3 MYLLbY5ie2ViQYPzZZk> M4DRUlEhcA>? NEXJNFZKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGYyOTd2TDDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkG2OUDPxE1? NWryVlRoOjR6MUmxNVY>
NIH-3T3 NVPTVGdDU2mwYYPlJGF{e2G7 MWixJIg> MXTJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjR5ODFOwG0> M17WZ|I1QDF7MUG2
NIH-3T3 MXLLbY5ie2ViQYPzZZk> MnvDNUBp NUO5VmExUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJyMmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6xOFgh|ryP NHvWUo8zPDhzOUGxOi=>
NIH-3T3 NUe0SI1UU2mwYYPlJGF{e2G7 NH7uZY8yKGh? MXnJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIEGxOVFVcW6|IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDNwMEO5JO69VQ>? NHHYV4QzPDhzOUGxOi=>
KARPAS299 NHS2XY9McW6jc3WgRZN{[Xl? M{joe|kxKG2rbh?= MX7EUXNQ M{f6UGlvcGmkaYTpc44hd2ZiTmDNMYZ2e2WmIFHMT{BxcG:|cHjvdplt[XSrb36g[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>? M3XKdFI1QTByN{Ww
MKN 45 M{G5UGtqdmG|ZTDBd5NigQ>? NHG5RZIyKGh? MVLEUXNQ NH;0VoFKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNkDPxE1? M2myTFI1QTByN{Ww
A549 M{TSWGN6fG:2b4jpZ{BCe3OjeR?= NEDYbGg1QCCq MX\EUXNQ NYnueXpmUUN3MDDv[kA1NjB6NDFOwG0> MkDGNlQ6ODB6M{C=
NCI-H1975 M1zJOGN6fG:2b4jpZ{BCe3OjeR?= NWLwV45uPDhiaB?= NVvmS2tpTE2VTx?= M{L1bGlEPTBib3[gO{42PTFizszN NEPwRXIzPDlyMEizNC=>
NCI-H1993 MV7DfZRwfG:6aXOgRZN{[Xl? M3H3fFQ5KGh? M1fVXWROW09? MkLQTWM2OCCxZjCwMlA3OSEQvF2= NVTjSWdmOjR7MEC4N|A>
NCI-H1993 M2HTZmFxd3Sxc3nzJGF{e2G7 NIrCV|gyKM7:TR?= NWG5TWhVOjRiaB?= NYTUNHBDTE2VTx?= Mmfs[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= NEPiTYwzPDlyMEizNC=>
NIH-3T3 MoX4R5l1d3SxeHnjJGF{e2G7 MVy0PEBp MYXEUXNQ M3:4[2lEPTBib3[gNE4{PjRizszN MXWyOFkxODh|MB?=
EBC1 NGPKdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG5UHdFPzJiaB?= MlP4SG1UVw>? NEnOSm1KSzVyIH;mJFAvODB4OTFOwG0> MWGyOFkxODh|MR?=
KARPAS299 NYPiOndbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXS3NkBp M1jEW2ROW09? NF23UJVKSzVyIH;mJFAvOiEQvF2= MXqyOFkxODh|MR?=
NB1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC4TWM2OD17MT65PEBvVQ>? NVftWYRHW0GQR1XS
NCI-SNU-5 M3zJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFyNT63OUBvVQ>? M3KxSXNCVkeHUh?=
SR MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3wR2lWUUN3ME2xNlYvOzFibl2= M3uyWnNCVkeHUh?=
SF539 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PGcmlEPTB;MkC0MlI1KG6P M2\BOXNCVkeHUh?=
SU-DHL-1 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPR[25PUUN3ME2zN|YvQDJibl2= NES3eHRUSU6JRWK=
SCC-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTN3Nj63OkBvVQ>? M1jiNnNCVkeHUh?=
DEL Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTN4OT65JI5O M{C1PXNCVkeHUh?=
CTV-1 NEj1XVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nkdmlEPTB;NUm2MlQ5KG6P MnTUV2FPT0WU
EM-2 NUnDc4ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj4TWM2OD14MEGuN|Qhdk1? NHvwOHVUSU6JRWK=
MHH-CALL-2 NVnJbW1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vRbmlEPTB;NkiyMlU4KG6P NVfnSmVRW0GQR1XS
KM12 NV3uRZFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTdyNj65JI5O MYjTRW5ITVJ?
KINGS-1 M4HKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\yTWM2OD15NEmuO|Uhdk1? MY\TRW5ITVJ?
MEG-01 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jVb2lEPTB;OEW3MlY3KG6P MoLjV2FPT0WU
BV-173 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTZTWM2OD1zLkC1PVk4KM7:TR?= M3nMdnNCVkeHUh?=
LAMA-84 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnKe5R2UUN3ME2xMlM5Ojh{IN88US=> MVfTRW5ITVJ?
KARPAS-299 NX\xTXpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PPVWlEPTB;MT60NFg3OSEQvF2= Mm[3V2FPT0WU
K-562 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\3cXpKSzVyPUGuO|IzPjlizszN NEjXOYJUSU6JRWK=
SK-LMS-1 NXjGcYFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwN{[4Olch|ryP NYq0[3ZjW0GQR1XS
MOLT-16 M1Syd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f3WmlEPTB;MT65OVU4PSEQvF2= MUTTRW5ITVJ?
CMK MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwOU[xOVkh|ryP NWrmNmFwW0GQR1XS
ST486 NHnYN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D2bWlEPTB;Mj60N|A4OyEQvF2= Mlj1V2FPT0WU
CI-1 MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrwbWhKSzVyPUKuOFk3PTlizszN NX7KZWcxW0GQR1XS
KP-N-RT-BM-1 NHriW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvqVGFKSzVyPUKuO|AyOjJizszN NYnwOFh2W0GQR1XS
ALL-PO MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvPcm13UUN3ME2zMlE5OjB5IN88US=> NGSxWZJUSU6JRWK=
KS-1 Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy2SI1OUUN3ME2zMlIyOjJ3IN88US=> NWXoV4NuW0GQR1XS
Becker NGq0fXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7GTWM2OD12LkKzPVMh|ryP NFq3dYJUSU6JRWK=
GDM-1 M3;pNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHrT4hwUUN3ME20MlI1PjF5IN88US=> MkPBV2FPT0WU
BC-1 NXjqOmNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwNEmyO|ch|ryP MY\TRW5ITVJ?
NB14 NVWydZJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\vOmVMUUN3ME20Mlg{PTJ2IN88US=> NUPyVpJIW0GQR1XS
NOS-1 NVTaU21ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f5V2lEPTB;NT6zN|g4PCEQvF2= MVTTRW5ITVJ?
MZ1-PC MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PmfWlEPTB;NT64NlE2OSEQvF2= NX61boRuW0GQR1XS
A498 NUjEfVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTZwMEi0O|Mh|ryP M2jyVnNCVkeHUh?=
EW-16 NGDRcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPSTWM2OD14LkO3O|c{KM7:TR?= MWjTRW5ITVJ?
NALM-6 NWD5S4lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHOVYFwUUN3ME22MlY5Ozh5IN88US=> NF;Gfm9USU6JRWK=
EB-3 NILHTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPvenBsUUN3ME23MlA4OjN|IN88US=> MVHTRW5ITVJ?
697 NVy3[3F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHETWM2OD17LkK0N|I6KM7:TR?= MXnTRW5ITVJ?
Ramos-2G6-4C10 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTlwNUm4OFIh|ryP MljSV2FPT0WU
KNS-81-FD Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXWTWM2OD17Lk[5OlU{KM7:TR?= Mnu4V2FPT0WU
HUTU-80 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm1TWM2OD17Lke0OlQzKM7:TR?= MXvTRW5ITVJ?
LS-411N M{KyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[3VZZKSzVyPUGwMlA2PjdizszN NYL1eWU3W0GQR1XS
RPMI-8402 M{GyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP6WXNKSzVyPUGwMlEyPiEQvF2= Ml3wV2FPT0WU
KU812 NGS5VZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDj[mJKSzVyPUGwMlI6QTFizszN MV;TRW5ITVJ?
EW-1 NXvzR4VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFyLkS0NlUh|ryP NVXNVFhWW0GQR1XS
HC-1 NHi0S2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFyLkS4OFQh|ryP MnP6V2FPT0WU
NB69 M2H4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP1fWVRUUN3ME2xNE42ODR|IN88US=> MWPTRW5ITVJ?
MFH-ino M1PUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrlTWM2OD1zMD64N|A{KM7:TR?= MXPTRW5ITVJ?
CCRF-CEM M37t[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj5VG5bUUN3ME2xNU42QTdizszN NY\LUWh2W0GQR1XS
SK-N-DZ NFXrOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS3blVLUUN3ME2xNk4xPDN4IN88US=> M{LFT3NCVkeHUh?=
NCI-H720 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTF{LkG3NFUh|ryP NIDyUIFUSU6JRWK=
HCC1187 MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTITWM2OD1zMj6yNFQyKM7:TR?= MV3TRW5ITVJ?
IST-SL2 M3XuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HnPGlEPTB;MUKuOFg4OiEQvF2= NUHsbHJ6W0GQR1XS
KE-37 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvWXYtKSzVyPUGyMlc6PjZizszN Ml\3V2FPT0WU
HCC1599 NVT5[mg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF{LkmwOlkh|ryP MUPTRW5ITVJ?
A4-Fuk MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF{Lkm1PFYh|ryP M1vSR3NCVkeHUh?=
NKM-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fuUGlEPTB;MUOuNlkzPSEQvF2= M1q2VnNCVkeHUh?=
BE-13 NWDCTmNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHjS4F6UUN3ME2xN{44QTh7IN88US=> MknDV2FPT0WU
MV-4-11 NXzBXm5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF2LkCzNlQh|ryP MXfTRW5ITVJ?
OPM-2 M1TTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDRVXNpUUN3ME2xOE41ODh3IN88US=> NHe3cIhUSU6JRWK=
KARPAS-422 M1LsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{SxXGlEPTB;MUSuOVEzPiEQvF2= NXizfGFKW0GQR1XS
RPMI-8226 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF2Lki5NVUh|ryP NX3acVQ4W0GQR1XS
KARPAS-45 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[2dZBTUUN3ME2xOU44PzF4IN88US=> MVvTRW5ITVJ?
SK-PN-DW NXjNbphsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF3Lki2N|Eh|ryP NV7oT2NVW0GQR1XS
LC-2 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTFTWM2OD1zNj6xOVA3KM7:TR?= Ml23V2FPT0WU
NCI-H1648 NYKycnZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL1RYRKSzVyPUG2MlI2PCEQvF2= NXnCRXhUW0GQR1XS
RL95-2 NFW5cpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF4LkO5O|gh|ryP MVXTRW5ITVJ?
KNS-42 Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi1bJpKSzVyPUG2MlczPzRizszN NHnGSI5USU6JRWK=
RPMI-6666 MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DZeWlEPTB;MU[uPVIyOSEQvF2= M3v3b3NCVkeHUh?=
SIG-M5 NWKzZ|RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HyfGlEPTB;MUeuNVkxOyEQvF2= NV\w[XdqW0GQR1XS
VA-ES-BJ NX3LOFBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX0TWM2OD1zNz63OFUyKM7:TR?= NHLZU|NUSU6JRWK=
MONO-MAC-6 MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF5LkmzNVIh|ryP MUnTRW5ITVJ?
LAN-6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjSdHNKSzVyPUG4Mlc2PTdizszN M36xV3NCVkeHUh?=
A388 NUPQb4lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnsPZZLUUN3ME2xPU4{ODV7IN88US=> NETwcWRUSU6JRWK=
SK-NEP-1 NHzae2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTDb3NKSzVyPUKwMlIyOzJizszN M{n1Z3NCVkeHUh?=
TE-10 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJyLkWyNlEh|ryP NXTzPVF[W0GQR1XS
HL-60 MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfwRmFHUUN3ME2yNE46ODl7IN88US=> MkjSV2FPT0WU
MC116 NEjSPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLXTWM2OD1{MT63NlIyKM7:TR?= M4\v[XNCVkeHUh?=
SW962 NYnGcGhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7aTWM2OD1{MT63PVE2KM7:TR?= M3u1TXNCVkeHUh?=
NOMO-1 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomyTWM2OD1{Mj62OVY1KM7:TR?= NXXHW482W0GQR1XS
CTB-1 NXrJc4pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLRUWlEUUN3ME2yNk45PjdzIN88US=> MmXnV2FPT0WU
MRK-nu-1 NYGydI1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjUTWM2OD1{Mj65NFc1KM7:TR?= NYfMTYpqW0GQR1XS
GR-ST MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L3bWlEPTB;MkOuO|Yh|ryP NF:1bWxUSU6JRWK=
HH MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLrTWM2OD1{ND6wNFMh|ryP M1ThdnNCVkeHUh?=
NCI-H1963 NV;hfmVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHoWXp3UUN3ME2yOE4xPzh{IN88US=> NIO2WFZUSU6JRWK=
QIMR-WIL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDLeW9KSzVyPUK0Mlg4PzJizszN NGOwfHBUSU6JRWK=
CGTH-W-1 M{jWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjmVWJKSzVyPUK1MlA4OjNizszN NF3rV5pUSU6JRWK=
LP-1 MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jLR2lEPTB;MkWuOlU2OSEQvF2= MUnTRW5ITVJ?
NCI-H748 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJ4LkWxN|ch|ryP NYnQToVxW0GQR1XS
PF-382 NVPFSpJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\l[FdnUUN3ME2yO{4zOjJ|IN88US=> NEjrS4VUSU6JRWK=
ATN-1 M3XPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jjS2lEPTB;MkeuN|c{OiEQvF2= MlP5V2FPT0WU
L-540 NEHDTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;BfWtiUUN3ME2yO{43PDV7IN88US=> NFO2eVhUSU6JRWK=
LXF-289 Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HzbWlEPTB;MkeuO|UyQSEQvF2= NIi1OmlUSU6JRWK=
LS-513 M{jCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ6LkG4NFch|ryP NUS1O3I1W0GQR1XS
NCI-H1581 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTNyLkO5O|Yh|ryP MYDTRW5ITVJ?
ES6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrEZnliUUN3ME2zNE43QDl7IN88US=> NF3PZ4NUSU6JRWK=
SW982 M4LISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrpTWM2OD1|MD64OVY3KM7:TR?= NWPnXlF[W0GQR1XS
DOHH-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNzLkW4PVMh|ryP NEHFXHhUSU6JRWK=
DB M3zSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfMV3lKSzVyPUOzMlk1OzFizszN M373UHNCVkeHUh?=
MPP-89 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T5cGlEPTB;M{SuNVc2PiEQvF2= M{PzTnNCVkeHUh?=
LB831-BLC M3i5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTN2LkWxPFQh|ryP NV3mO|dlW0GQR1XS
NB5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfw[3ZKSzVyPUO0Mlg2OzVizszN M1LD[nNCVkeHUh?=
GB-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LxWWlEPTB;M{WuNFQ3QSEQvF2= MUPTRW5ITVJ?
TE-15 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfPUYw4UUN3ME2zOU4zOjN6IN88US=> NHnuOVdUSU6JRWK=
LC4-1 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PUOmlEPTB;M{WuN|g1PyEQvF2= NFHydWlUSU6JRWK=
NCI-H747 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTyTWM2OD1|Nj6xN|Y6KM7:TR?= NVWzS4JEW0GQR1XS
NTERA-S-cl-D1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PvdWlEPTB;M{iuO|M1PyEQvF2= M3\3TnNCVkeHUh?=
SK-MM-2 M12zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3yTWM2OD12MD6xNVQ3KM7:TR?= MUHTRW5ITVJ?
TGW MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfXTWM2OD12MT6wOVY{KM7:TR?= M{XXSHNCVkeHUh?=
ONS-76 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonxTWM2OD12Mj60PFg{KM7:TR?= NVPx[HFRW0GQR1XS
CPC-N Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnPSW04UUN3ME20Nk46QTdzIN88US=> M322W3NCVkeHUh?=
ES4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPvVJlKSzVyPUS0MlQyPTNizszN NVS4N5BjW0GQR1XS
Daudi M1\1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLtTWM2OD12NT6wPFI4KM7:TR?= MUnTRW5ITVJ?
MOLT-4 MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n4R2lEPTB;NEWuNFg2OyEQvF2= NV6yNGRYW0GQR1XS
HT-144 NYPzXnNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfic5ozUUN3ME20Ok44OjZizszN M3zCV3NCVkeHUh?=
SW872 NW[1NFk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXG[pRKSzVyPUS4MlE6OzNizszN NITL[2ZUSU6JRWK=
D-283MED MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzZendKSzVyPUS4MlM2PDJizszN MULTRW5ITVJ?
NCI-H2126 NW\wbFNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;M[phKSzVyPUS4Mlg1PzZizszN MnjqV2FPT0WU
NCI-SNU-16 NULxWWdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XRWGlEPTB;NEmuNlE1OyEQvF2= NXWydpU5W0GQR1XS
CESS NEfKWpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X0N2lEPTB;NEmuOVA5QCEQvF2= MX\TRW5ITVJ?
A101D NGP1d|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vFRWlEPTB;NEmuPVc{PiEQvF2= M1\B[3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

体内研究 PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm3) 明显衰退,且按43天处理日程处理后,平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上,完全抑制GTL-16肿瘤生长,PF-2341066每天按50 mg/kg剂量处理小鼠,3个月后,只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天,观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型,处理周期为33天,观察到平均肿瘤体积降低53%,且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长,在实验最后一天,抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型,不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤,观察到CD31阳性内皮细胞显著降低,这种作用存在剂量依赖性,说明 MVD 受抑制,且具有相关的抗癌高效性,这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型,显著降低人VEGFA 和IL-8血浆水平,这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤,观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠,具有抗癌高效性,这种作用存在剂量依赖性,处理15天,所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器,及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂,这些与 NPM-ALK 磷酸化和功能受抑制相关。[2] PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长(例如, 增殖和存活)和转移 (例如,入侵和形成克隆)。PF-2341066口服饲喂裸鼠,抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤,引起肿瘤衰退,这与18F-FDG 摄取的缓慢降低相关,且降低葡糖糖转运蛋白 1, GLUT-1的表达。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

生化激酶实验:

使用连续耦合的分光光度测定c-Met催化活性,通过分析NADH消耗率而测定c-Met诱导的ADP产量,这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定Ki值, 在含实验试剂的实验孔中加入不同浓度PF-2341066,然后在37oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验:

[1]

+ 展开
  • Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞
  • Concentrations: 0 nM-256 nM
  • Incubation Time: 1小时
  • Method:

    GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上,孔中含培养基,培养基中含10% 胎牛血清(FBS),然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)],处理 24小时。 在调查配体依赖的RTK 磷酸化实验中,加入相应的生长因子,处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时,然后使用含 1 mmol/L Na3VO4的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化,使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时,在4oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸(PY-20)抗体(1:500)中温育20分钟;(d) 再次冲洗7次;(e)在3,3,5,5-四甲基联苯胺过氧化物酶底物中温育,开始显示反应,加入0.09 N H2SO4终止反应; (f)在450 nm 处使用分光光度计测定吸光度。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 450.34
化学式

C21H22Cl2FN5O

CAS号 877399-52-5
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03737994 Not yet recruiting ALK Gene Rearrangement|ALK Positive|Non-Squamous Non-Small Cell Lung Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 National Cancer Institute (NCI) January 13 2019 Phase 2
NCT03672643 Not yet recruiting ALK-positive NSCLC Pfizer December 28 2018 Phase 4
NCT03707847 Recruiting ALK-Positive Anaplastic Large Cell Lymphoma Mingzhi Zhang|Zhengzhou University October 1 2018 Phase 4
NCT03646994 Recruiting Effectiveness and Safety for Real World Study on Crizotinib Used for ROS1 Arranged Non-squamous Non-small Cell Lung Cancer Hunan Province Tumor Hospital August 1 2018 --
NCT03647111 Recruiting Non-small Cell Lung Cancer Hunan Province Tumor Hospital August 1 2018 --
NCT03620643 Not yet recruiting Lobular Breast Carcinoma|Gastric Cancer Royal Marsden NHS Foundation Trust|Pfizer|Breast Cancer Now August 13 2018 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • 回答:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品

Tags: 购买Crizotinib (PF-02341066) | Crizotinib (PF-02341066)供应商 | 采购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)价格 | Crizotinib (PF-02341066)生产 | 订购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID